2021 EBMT Annual Meeting

home / publications / supplements / 2021-ebmt-annual-meeting

Coverage of the 2021 EBMT Annual Meeting, held virtually March 14-17, 2021.

Sergio A. Giralt, MD, of Memorial Sloan Kettering Cancer Center

Dr. Giralt on the Potential Utility of Omidubicel in Hematologic Malignancies

Sergio A. Giralt, MD
March 16th 2021
Video

Sergio A. Giralt, MD, discusses the potential utility of omidubicel in hematologic malignancies.

Alessandro Rambaldi, MD

Narsoplimab Elicits Responses Across High-Risk HSCT-TMA Subtypes

Jessica Hergert
March 16th 2021
Article

The MASP-2 inhibitor narsoplimab demonstrated high response rates and a significant improvement in laboratory markers and organ function irrespective of subgroup in adult patients with high-risk hematopoietic stem cell transplant–associated thrombotic microangiopathy.

Carolyn Mulroney, MD

AB-205 Shows Tolerability, Robust Effects in Patients With Lymphoma Undergoing HDT-ASCT

Gina Mauro
March 16th 2021
Article

The engineered cord endothelial cell product AB-205 showed an encouraging safety profile along with robust effects in eliminating oral/gastrointestinal severe regimen-related toxicities in patients with systemic lymphoma undergoing high-dose therapy and autologous hematopoietic stem cell transplantation.

Guillermo F. Sanz, MD, PhD

Omidubicel Showcases Promising Outcomes in High-Risk Hematologic Cancers Following Myeloablation

Gina Mauro
March 15th 2021
Article

Omidubicel was associated with a significantly improved median time to neutrophil engraftment compared with standard umbilical cord blood transplantation in patients with high-risk hematologic malignancies.